Cory berkland.

Cory Berkland Chronic iron overload is a serious condition that develops as a consequence of long-term accumulation of iron, eventually overwhelming iron storage systems and causing oxidative ... A Kaviratna and P Dhar would like to acknowledge support from the Jay Award from the Higuchi Biosciences Center and the NIH (Award number: P20GM103638). N El-Gendy and C Berkland would like to acknowledge support from the Coulter Foundation and the NSF (Award number: CHE 0966614).So Cory Berkland and colleagues set out to find new kinds of pharmaceuticals to fight weight gain. Targeting the body's process of absorbing fat, the researchers designed a class of polymers that capture fat particles called micelles in the intestines so they can't be digested. Instead, they pass through the gut and are excreted.Berkland is currently serving as the commander, 354th Fighter Wing, Pacific Air Forces, Eielson Air Force Base, Alaska. Air Force Col. Amy S. Bumgarner for appointment to the grade of brigadier ...Cory Berkland 1 , C Russell Middaugh 2 Affiliations 1 a Department of Chemical and Petroleum Engineering and Department of Pharmaceutical Chemistry , The University of Kansas , Lawrence , KS , USA.

Cory Berkland. Download Free PDF View PDF. Nature Nanotechnology. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. 2012 • Ciro Chiappini, Michael Evangelopoulos, Lucas Isenhart, Ennio Tasciotti. Download Free PDF View PDF.

Cory Berkland Mario Rivera Kate ESHELMAN Jian QIAN Nashwa EL-GENDY Original Assignee The University Of Kansas Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2014-10-10 Filing date 2015-10-08 …

Recipient Qun Wang, and former advisor, Cory Berkland, University of Kansas. Postdoctoral Fellowship Award selection chair Kinam Park (left) and CRS Foundation chair Susan Cady (right) after presenting Qun Wang (center) with the 2010 Jorge Heller Postdoctoral Fellowship.Cory Berkland · Aug 9 '20. Our lab at The University of Kansas has partnered with Sean and the Foothold Labs team. I have been impressed by the sensitivity and accuracy of the NanoRev system. Sean and his colleagues have been reliable and results-oriented collaborators.He received MS and PhD degrees from the Department of Chemical and Biomolecular Engineering at the University of Illinois in Urbana-Champaign and a BS degree in Chemical Engineering from Iowa State University in Ames. Prof. Berkland is a co-founder of Orbis Biosciences, Savara Pharmaceuticals, Bond Biosciences and Orion BioScience. Nashwa El-Gendy, Mark M. Bailey, Cory Berkland; Pages 283-312. Liposomes for Pulmonary Drug Delivery. Janani Swaminathan, Carsten Ehrhardt; Pages 313-334. Nanoparticles for Pulmonary Delivery. Alan B. Watts, Robert O. Williams III; Pages 335-366. Pulmonary Delivery of Plasmid DNA for Disease Prevention and Therapy.INTRODUCTION. Autoimmune diseases such as multiple sclerosis (MS) are typified by a breakdown of healthy immune regulation and subsequent misrecognition of self for non-self. 1–2 The autoimmune breakdown in MS is largely propagated by autoreactive T and/or B cell clonal expansion and attack against myelin sheath autoantigens, leading to demyelination and neurodegeneration. 3–6 Activation ...

Nashwa El-Gendy 1 , Eric M Gorman, Eric J Munson, Cory Berkland. Affiliation 1 Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas 66047, USA. PMID: 19130469 PMCID: PMC4610389 DOI: 10.1002/jps.21630 Abstract Nanoparticle technology represents an attractive approach for formulating poorly water-soluble pulmonary ...

Cory Berkland. 2004, Journal of Controlled Release. A thorough understanding of the factors affecting drug release mechanisms from surface-erodible polymer devices is critical to the design of optimal delivery systems. Poly(sebacic anhydride) (PSA) microspheres were loaded with three model drug compounds (rhodamine B, p-nitroaniline and ...

KU chemical and petroleum engineering associate professors Michael Detamore and Cory Berkland are collaborating on the project that could revolutionize the repair and treatment of degenerated cartilage. "Cartilage doesn't really heal well on its own," Detamore said. "It's not like bone where you put it in a cast, wait six weeks and ...Cory Berkland is a founder of, and advisor to, Orbis Biosciences, Inc. and Savara Pharmaceuticals, Inc. Additionally, both Cory Berkland and Mark Bailey are named as inventors on patents and/or patent applications relating to technologies described in this article. Part of this work was supported by NIH grants R03 AR054035 and P20 RR016443.Cory Berkland Many current therapies for autoimmune diseases such as multiple sclerosis (MS) result in global immunosuppression, rendering insufficient efficacy with increased risk of adverse side ...Cory Berkland is a professor of pharmaceutical chemistry and chemical and petroleum engineering at the University of Kansas. (Berkland Tr. 593) The Court recognized Dr. Berkland as an expert in the preparation and analysis of pharmaceutical formulations.Cory Berkland Magnetic nanoparticles that display high saturation magnetization and high magnetic susceptibility with a size less than 200 nm are of great interest for medical applications.Joe Scherrer. Executive Director, Henry Edwin Sever Institute Director, Cybersecurity Strategic Initiative Program Director, Graduate Studies in Cybersecurity Management.

Supang Khondee, Tatyana Yakovleva, Cory Berkland. First published: 04 August 2010. https://doi.org/10.1002/app.32460. Citations: 2. Read the full text. PDF. …The following articles are merged in Scholar. Their combined citations are counted only for the first article.Berkland, Cory J. Publisher. Elsevier. Type. Article. Article Version. Scholarly/refereed, author accepted manuscript. Rights. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License 3.0 (CC BY-NC-ND 3.0 US), which permits use and distribution in any medium, provided the original work is ...Dr. Cory Berkland Solon E. Summerfield Distinguished Professor School of Engineering, School of Pharmacy Chemical and Petroleum Engineering, Pharmaceutical Chemistry RESEARCH INTERESTSAntigen-specific immunotherapies, sequestering cells to combat autoimmunity, autoimmunity and tolerance reintroduction, targeted drug delivery, and …Dr. Cory Berkland. Solon E. Summerfield Distinguished Professor. School of Engineering, School of Pharmacy. Chemical and Petroleum Engineering, Pharmaceutical Chemistry. …

As an alternative, nanoparticles may be targeted to a specific tissue with up-regulated cell adhesion molecules such as intercellular cell-adhesion molecule-1 (ICAM-1), which is dramatically up-regulated (~10 fold or more) on the vascular endothelium in response to the increased production of proinflammatory cytokines such as interleukin-1-β ...Cory Berkland, Departments of Pharmaceutical Chemistry and Chemical & Petroleum Engineering, University of Kansas, 2030 Becker Drive, Lawrence, KS 66047, USA. E-mail: [email protected] Read the full text

Autoantigen-specific immunotherapy using peptides offers a more targeted approach to treat autoimmune diseases, but the limited in vivo stability and uptake of peptides impedes clinical implementation. We previously showed that multivalent delivery of peptides as soluble antigen arrays (SAgAs) efficiently protects against spontaneous autoimmune diabetes in the non-obese diabetic (NOD) mouse model.INTRODUCTION. Investigations into the molecular processes involved in antigen recognition have led to new approaches in the design and administration of vaccines (1, 2).Traditionally, vaccines generate a robust immune response to a particular antigen by adsorbing the antigen to an alum particle surface (3–5).Though individual alum particles …What We Do. Our lab works at the interface of medicine and engineering with an emphasis on precisely controlling the physical and chemical properties of particles and biomaterials. The lab environment fosters multidisciplinary interaction between graduate and undergraduate researchers from the departments of Chemical and Petroleum Engineering ... Cory BerklandDepartment of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Kansas, USA; [email protected] · ORCID Icon http ...In recent history, through the merger of engineering and biological sciences, biotechnology has pressed toward improving methods for regenerating tissues, developing biosensors, and effectively delivering therapeutic agents. Nashwa El-Gendy1,3, Warangkana Pornputtapitak1, and Cory Berkland1,2,* 1Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66047. ... Fax: (001) 785- 864- 1454. [email protected]. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to ourCory Berkland Solon E. Summerfield Distinguished Professor Department of Pharmaceutical Chemistry Contact Info [email protected] 785-864-1455 Multidisciplinary Research Building, Room 320E 2030 Becker Drive Lawrence, KS 66047 Personal Links Cory Berkland Research Education — Ph.D. in Chemical and Biomolecular Engineering, University of IlliniosChuda Chittasupho, 1 Joshua Sestak, 2 Laura Shannon, 3 Teruna J. Siahaan, 2 Charlotte M. Vines, 3 and Cory Berkland 2, 4 Chuda Chittasupho 1 Department of Pharmaceutical Technology, Faculty of Pharmacy, Srinakharinwirot University, 63 Mu 7 Rangsit-Nakhonnayok Road, Ongkharak, Nakhonnayok, 26120, ThailandAbstract: Particles for delivery of active ingredients formed from an active ingredient and a hydrophobic matrix, as well as methods for making such particles. Type: Grant. Filed: August 16, 2019. Date of Patent: February 14, 2023. Assignee: ADARE PHARMACEUTICALS USA, INC. Inventors: Cory Berkland, Milind Singh.

Cory Berkland, Ph.D.-Solon E. Summerfield Distinguished Professor-Chemical and Petroleum Engineering-Pharmaceutical Chemistry; View full profile .

Cory Berkland. [email protected]; Department of Chemical and Petroleum Engineering, University of Kansas, Lawrence, Kansas 66047. Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047. Department of Chemical and Petroleum Engineering, University of Kansas, Lawrence, Kansas 66047Search for more papers by this author

Congratulations to our collaborator, Prof. Cory Berkland, who was recognized last week with the Jim Baxendale Commercialization Award! Prof. Berkland...Two of the co-founders of Orion, Dr. Joshua Sestak and Prof. Cory Berkland, have invented disruptive technologies that Orion is developing to provide both immediate relief and long-term solutions ...Corporate Faith - 2023 Business Speakers Series - Cory Berkland. Mon, Aug 14, 6:00 PM. Undivided Experience Center • Chesterfield, MO. Free. Save Corporate Faith - 2023 Business Speakers Series - Cory Berkland to your collection.Mark M Bailey 1 , Cory Berkland. Affiliation 1 Department of Chemical & Petroleum Engineering, University of Kansas, Lawrence, KS 66047, USA. PMID: 22816117 DOI: 10.4155/tde.10.15 Abstract Novel technologies to enhance therapeutic delivery and biomaterial performance are fundamental to the development of improved products with fewer unwanted ...Complexes were formed by addition of appropriate volumes of pDNA and TAT with or without CaCl 2 (15 μL of 113 mM CaCl 2) or PEI solutions calculated to produce the desired molar ratio, followed by a 20 min incubation at 4 °C prior to use (Baoum and Berkland, 2011). Complexes were freshly prepared before each individual analysis. 2.3.BME Faculty Directory. Cardiovascular Engineering. Orthopedic Engineering. Women's Health Technologies.Cory Berkland, CEO [email protected]. Release Summary. Phase Ia/b will assess the safety of BBI-001 and test the ability of BBI-001 to prevent iron uptake from food. Contacts.Abdulgader Baoum, 1 Sheng-Xue Xie, 1 Amir Fakhari, 2 and Cory Berkland 1, 3, 4 Abdulgader Baoum 1 Department of Pharmaceutical Chemistry, The University of Kansas, 2030 Becker Drive, Lawrence, Kansas 66047, USA

Hartwell BL; Pickens CJ; Leon M; Berkland C, Multivalent Soluble Antigen Arrays Exhibit High Avidity Binding and Modulation of B Cell Receptor-Mediated Signaling to Drive Efficacy against Experimental Autoimmune Encephalomyelitis. Biomacromolecules 2017, 18 (6), 1893–1907. [PMC free article] [Google Scholar]liquid droplets (Berkland et al. 2001). A schematic diagram of the PPF nozzle is illustrated in Figure 1. The PLGA/ analyte solution is forced via a syringe pump (New Era Pump Systems, Wantagh, NY) through a 22-gauge hypo-dermic needle at flow rates from 1-10 mL h 1. An annular immiscible stream of water containing a mass concentra-The main apparatus (Fig. 1A), which provides fabrication of monodisperse microparticles, is based on passing a solution containing the sphere material, and any drug to be encapsulated, through a small nozzle or other orifice (20 μm to a few millimeters in diameter) to form a smooth, cylindrical jet.To controllably break the jet into droplets, the nozzle is vibrated by a piezoelectric ...Instagram:https://instagram. what does color guard dotiffany jefferschase bank morehead city ncathletic com Cory Berkland Songyot Anuchapreeda: Authors: Fah Chueahongthong Singkome Tima Sawitree Chiampanichayakul Cory Berkland Songyot Anuchapreeda: Keywords: Biochemistry, Genetics and Molecular Biology;Chemistry;Pharmacology, Toxicology and Pharmaceutics: Issue Date: 1-Oct-2021: Abstract: virtue ethics and abortionpaul mills basketball Cory Berkland. Cory Berkland. Solon E. Summerfield Distinguished Professor. Department of Pharmaceutical Chemistry. Contact Info. [email protected]. is grady dick gay Hartwell BL; Pickens CJ; Leon M; Berkland C, Multivalent Soluble Antigen Arrays Exhibit High Avidity Binding and Modulation of B Cell Receptor-Mediated Signaling to Drive Efficacy against Experimental Autoimmune Encephalomyelitis. Biomacromolecules 2017, 18 (6), 1893–1907. [PMC free article] [Google Scholar]“The closing of our Series B financing will strengthen the development program for BBI-001 and advance our pipeline of non-absorbed, oral therapies,” said Dr. …